Astrazeneca (AZN) EBIT (QoQ) (2009 - 2026)
Astrazeneca (AZN) EBIT (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.53 Bn | 631.77 Bn | 17.26 Bn |
| 2 | AbbVie | 469.73 Bn | 463.16 Bn | 12.70 Bn |
| 3 | Merck | 376.02 Bn | 368.88 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.79 Bn | 252.89 Bn | 12.86 Bn |
| 6 | Amgen | 236.51 Bn | 222.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 182.32 Bn | 179.14 Bn | 6.22 Bn |
| 8 | Pfizer | 159.52 Bn | 147.82 Bn | 10.94 Bn |
| 9 | Gsk | 106.18 Bn | 102.01 Bn | 8.24 Bn |
| 10 | Sanofi | 55.17 Bn | 47.79 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.48% |
| Mar 31, 2026 | 42.58% |
| Dec 31, 2025 | -16.89% |
| Sep 30, 2025 | 2.14% |
| Jun 30, 2025 | -4.52% |
| Mar 31, 2025 | 80.45% |
| Dec 31, 2024 | -3.32% |
| Sep 30, 2024 | -23.31% |
| Jun 30, 2024 | -11.85% |
| Mar 31, 2024 | -55.24% |
| Dec 31, 2023 | 256.14% |
| Sep 30, 2023 | -20.44% |
| Jun 30, 2023 | -3.65% |
| Mar 31, 2023 | -4.28% |
| Dec 31, 2022 | 113.90% |
| Sep 30, 2022 | 130.98% |
| Jun 30, 2022 | -38.61% |
| Mar 31, 2022 | 400.68% |
| Dec 31, 2021 | 82.56% |
| Sep 30, 2021 | -248.54% |